AFMD – affimed n.v. (US:NASDAQ)
Stock Stats
News
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $30.00 to $25.00. They now have an "overweight" rating on the stock.
Affimed (NASDAQ: AFMD) had its price target raised by analysts at Stifel Nicolaus from $1.00 to $5.00. They now have a "hold" rating on the stock.
Affimed (NASDAQ: AFMD) had its price target raised by analysts at HC Wainwright to $10.00. They now have a "buy" rating on the stock.
Form 6-K Affimed N.V. For: Mar 28
Form 20-F Affimed N.V. For: Dec 31
Form 6-K Affimed N.V. For: Mar 11
Form 6-K Affimed N.V. For: Mar 06
Form SC 13G/A Affimed N.V. Filed by: Ridgeback Capital Investments L.P.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.